TabsDetailsBasic DetailsDate Posted: Thursday, September 12, 2019Status: CompleteMedical Product: bendroflumethiazide (BFMTZ), chlorothiazide (CTZ), hydrochlorothiazide (HCTZ)Health Outcome(s): non-melanoma skin cancerDescription: The goal of this request was to investigate the occurrence of non-melanoma skin cancer (NMSC) diagnoses among incident users of thiazide diuretics or comparator drugs of interest and to observe follow-up time after incident drug dispensing in the Sentinel Distributed Database (SDD). Data from January 1, 2000 to October 31, 2017 from 17 Data Partners contributing to the SDD were included in this report. Read More Deliverables (1)Sentinel Modular Program Report: Non-Melanoma Skin Cancer following Hydrochlorothiazide UseAdditional InformationAdditional DetailsFDA Center: CDERTime Period: January 1, 2000 - October 31, 2017Study Type: Modular ProgramAssessment Type: Exploratory AnalysesPopulation / Cohort: All individualsData Sources: Sentinel Distributed Database (SDD)Related Links: Non-Melanoma Skin Cancer following Hydrochlorothiazide Use: A Propensity Score Matched AnalysisDuration of Use Among New Users of Hydrochlorothiazide (HCTZ), Angiotensin-Converting Enzyme Inhibitors (ACEIs), and Angiotensin II Receptor Blockers (ARBs)
